Hoth Therapeutics "announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,000,000 shares of its common stock and warrants to purchase up to an aggregate of 2,500,000 shares of common stock, at a purchase price of $5.00 per share and accompanying warrant in a private placement priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the private placement are expected to be $10 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The private placement is expected to close on or about January 3, 2023, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HOTH:
- After Massive Rally, HOTH Tanks on Private Placement
- Hoth Therapeutics Skyrockets after FDA Greenlight for Skin Therapy Trial
- Hoth Therapeutics announces FDA acceptance of IND application for HT-001
- Biotech Alert: Searches spiking for these stocks today
- Hoth Therapeutics announces submission of IND application for HT-001